Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 Study of Abarelix in Androgen-Independent Prostate Cancer
NCT00100243Phase 2Completed
- Sponsor
- Praecis Pharmaceuticals Incorporated
- Start
- May 2004
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of abarelix in prostate cancer (PCa), sponsored by Praecis Pharmaceuticals Incorporated. Started May 2004; status: completed.
02
Drugs
abarelix
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT00100243.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00100243.